Thanks to proactive R&D work and robust product registration, Actavis launched more generic pharmaceuticals in 2007 than ever before: 504, to be precise.

With 650 products on the market and over 400 projects in our pipeline, our portfolio is one of the strongest in its field.

Actavis’ R&D division set yet another record in 2007 for its number of finalised products in development, both in Europe and in the US. Another record was set in Actavis’ regulatory submission activity.